Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial

• Main Authors: Bhagirath B. Solanki (Author), Christine Juergens (Author), Manojkumar B. Chopada (Author), Pravin Supe (Author), Vani Sundaraiyer (Author), Natacha Le Dren-Narayanin (Author), Mark W. Cutler (Author), William C. Gruber (Author), Daniel A. Scott (Author), Beate Schmoele-Thoma (Author)
• Format: Book
• Published: Taylor & Francis Group, 2017-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Streptococcus pneumoniae infection is a major global public health concern in older adults, especially as life expectancy continues to increase in most countries, including India. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) with the ability to enhance immunity (immunologic memory) o...